期刊文献+

RP-HPLC法测定米铂的含量 被引量:1

Determination of miriplatin by RP-HPLC
下载PDF
导出
摘要 目的建立以反相高效液相色谱法测定米铂含量的方法。方法色谱柱为十八烷基硅烷键合硅胶柱(C_(18),4.6 mm×150 mm,5μm),流动相为叔丁醇-乙腈(9∶1),流速:1.0 m L·min^(-1),柱温:30℃,紫外检测波长:220 nm,进样量:20μL。结果米铂在40.68~305.10μg·m L^(-1)的检测浓度内呈良好的线性关系,R^2=1;平均回收率为100.13%(n=9),RSD为0.15%。结论本方法简便、快速、准确,回收率好,可用于米铂的含量测定。 Objective To establish a RP- HPLC method for the determination of miriplatin. Methods The ostade-cylsilane column( C_(18),4. 6 mm × 150 mm,5 μm) was used,the mobile phase was tertiary butyl alcohol- acetonitrile( 9∶1),the flow rate was 1. 0 m L·min^(-1),the column temperature was 30 ℃,the detection wavelength was 220 nm,the injection volume was 20 μL. Results A good linear was obtained in the range of 40. 68 ~ 305. 10 μg·m L^(-1)( R^2= 1). The average recovery was 100. 1%( n = 9),with RSD of 0. 15%. Conclusion The method was convenient,rapid,accurate and good recovery,it can be used for the determination of miriplatin.
作者 范振华
出处 《药学研究》 CAS 2016年第1期25-26,40,共3页 Journal of Pharmaceutical Research
关键词 反相高效液相色谱法 米铂 含量测定 RP-HPLC Miriplatin Determination
  • 相关文献

参考文献11

二级参考文献98

  • 1Jin Iwazawa,Shoichi Ohue,Keigo Yasumasa,Takashi Mitani.Transarterial chemoembolization with miriplatin-lipiodol emulsion for neuroendocrine metastases of the liver[J].World Journal of Radiology,2010,2(12):468-471. 被引量:2
  • 2翁琳,陈凌亚.铂类金属抗肿瘤药物的应用与研究进展[J].中国药学杂志,2005,40(16):1205-1208. 被引量:9
  • 3栾成章,祝波,王尊文,王亮.顶空气相色谱法测定夫西地酸中有机溶剂残留量[J].中国药房,2006,17(7):535-536. 被引量:12
  • 4李桂杰,周祝谦,王连祥.经肝动脉化疗栓塞术[J].山东医药,2006,46(17):87-88. 被引量:2
  • 5KISHIMOTO S, NOGUCHI T, YAMAOKA T, et al. In vitro release of SM-11355, cis[ ( ( iR, 2R) -1,2-cyclohexanediamine-N, N') bis(myristato) ] platinum (II) suspended in lipiodol [ J 1. Biol Pharm Bull, 2000, 23 (5) : 637 - 640.
  • 6HANADA M, BABA A, TSUTSUMISHITA Y, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis [ J]. Cancer Chemoth Pharm, 2009, 64 (3) : 473 - 483.
  • 7FUJIYAMA S, SHIBATA J, MAEDA S, et al. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodo| [J]. BrJCancer, 2003, 89(9): 1614-1619.
  • 8KISHIMOTO S, NOGUCHI T, YAMAOKA T, et al. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration[J]. Biol Pharm Bull, 2000, 23(3) : 344 -348.
  • 9KISHIMOTO S, MIYAZAWA K, TERAKAWA Y, et al. Cytotoxicity of cis-[ ( ( 1R ,2R) -1,2-cyclohexanediamine-N,N') bis( myristato) l-platinum(II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line[ J ]. Jpn J Cancer Res, 2000, 91(12) : 1326 -1332.
  • 10OKUSAKA T, OKADA S, NAKANISHI T, et al. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355 ) in patients with hepatocellular carcinoma [ J]. Invest New Drugs, 2004, 22(2) : 169 -176.

共引文献44

同被引文献8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部